CORT has opened the Wyeth 3144A2 3005 WW Study testing the oral her-2 inhibitor, neratinib, in combination with paclitaxel (Taxol), versus standard therapy with trastuzumab (Herceptin) in combination with paclitaxel, for first-line treatment of her-2+ metastatic breast cancer.
Neratinib is an oral anti-her-1/her-2 drug with demonstrated efficacy in metastatic her-2 positive breast cancer. The safety studies have demonstrated acceptable and manageable toxicity of neratinib, including rash and occasional loose stools or diarrhea being most common. As with other her-2 inhibiting drugs, neratinib may lower the cardiac ejection fraction, so serial monitoring of cardiac function is routine. The Phase III study will compare the efficacy and tolerability of paclitaxel with either oral neratinib or trastuzumab (a monoclonal antibody against her-2 protein, given IV).
The potential advantages of neratinib include improved convenience (and possibly improved safety). The drug is given orally.
For more information about this study, visit our website at www.CORTPA.com, or contact a Research Coordinator at 972-566-5588.
Patients with her-2+ breast cancer may also be eligible for other studies and treatment at CORT, including non-study therapy. The principle investigator at CORT is Dr. Barry Mirtsching. He has personally conducted over 200 trials in cancer therapy over 16 years, many in breast cancer management. Experience in both trial and non-trial breast cancer management benefits patients by producing better treatment outcomes. Care at CORT is individual and personal, with adequate time for problem-solving and direct contact with the physician.
Tags: Breast Cancer, clinical trial, Dallas, first-line, her-2 positive, Herceptin, metastatic breast cancer, neratinib, paclitaxel, Texas, trastuzumab
September 6, 2009 at 3:19 am |
[...] Go here to read the rest: New Treatment for Her-2+ Metastatic Breast Cancer Opens at CORT … [...]
September 28, 2009 at 9:31 pm |
Hi, mi wife is fighting a old metastatic breast cancer since 2000.
She received a lot of chemo(200), taxotere,herceptin and now, Abraxanne.
With Abraxanne, the cancer did not progres. She tries to come back to taxotere and cancer grow up.
Is neratinib could be use with abraxanne ?
I suppose that if it’s possible teh result could be very good.
We are Canadian (québec) and research are always in late here.
I know she won’t abel to receive an other 200 chemo(side effects) and i’m looking to find other solutions.
The question is : could you help us ?
Thanks
Yves Paquet
September 28, 2009 at 10:59 pm |
This drug is only available on clinical study, in first-line use (initial therapy). There is no data about using it in other situations. Your physicians should be able to point you to trials and/or other therapies for metastatic her-2+ breast cancer. There are many other standard therapies that are not taxance (taxol, taxotere, abraxane).
BCM